Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 14/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664370 | 0.90 | MEN1 (0.54) | RXFP1P2RX1SLC2A1P2RX4P2RX7 | |
| SCHEMBL330133 | 0.87 | P2RX1 (0.73) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL17664198 | 0.87 | RXFP1 (0.53) | RXFP1LCKKDRTEKMAPT | |
| SCHEMBL21416909 | 0.86 | RXFP1 (0.46) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL25231718 | 0.84 | MEN1 (0.67) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL29537581 | 0.84 | MEN1 (0.67) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL20577892 | 0.84 | P2RX1 (0.60) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL26075815 | 0.83 | P2RX1 (0.59) | RXFP1P2RX1PTGS1SLC2A1P2RX4 | |
| SCHEMBL13202464 | 0.81 | RXFP1 (0.62) | RXFP1P2RX1PTGS1LCKMAPT | |
| SCHEMBL26077933 | 0.81 | P2RX1 (0.56) | RXFP1P2RX1PTGS1SLC2A1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | RXFP1 3174/4885P2RX1 478/4885PTGS1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.